Wen-Kai Weng, MD, PhD

BMT specialist, Lymphoma specialist, Medical oncologist, Multiple myeloma specialist

Assistant Professor of Medicine (Blood and Marrow Transplantation) and, by courtesy, of Dermatology at the Stanford University Medical Center

Blood and Marrow Transplant Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Lymphoma Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Medical Education: Chungshan Medical College (1988)

University of Minnesota (1996) MN

Internship: University of Texas Medical School (1997) TX

Residency: University of Texas Medical School (1999) TX

Fellowship: Stanford University School of Medicine (2002) CA

Board Certification: Internal Medicine, American Board of Internal Medicine (2007)

Board Certification: Medical Oncology, American Board of Internal Medicine (2008)

Honors & Awards

Translational Research Grant, Stanford Cancer Institute (2014-2015)

Division Teaching Award, BMT, Stanford University (2012)

Developmental Research Award, Stanford Cancer Institute (2012-2013)

ITI Seed Grant Award, Institute for Immunity, Transplantation and Infection, Stanford University (2011-2012)

Division Teaching Award, BMT, Stanford University (2010)

Developmental Research Award, Stanford University Cancer Center (2009-2010)

Division Teaching Award, BMT, Stanford University (2009)

K08 Clinical Scientist Career Development Award, NIH/NCI (2005-2009)

Fellowship, Lymphoma Research Foundation (2002-2004)

Charles and Dorothy Andrew Bird Award, Sigma Xi Scientific Research Society (1996)

Doctoral Dissertation Award, University of Minnesota Graduate School (1995)

Predoctoral National Research Service Award, NIH/NIAID (1994-1995)

Administrative Appointments

Scientific Advisory Board, Lymphoma Research Foundation (2011 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Targeting CD137 enhances the efficacy of cetuximab.
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., & Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. journal of clinical investigation, 124(6), 2668-2682.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma
Weng, W. K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214).

Cancer Vaccines and T Cell Therapy
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., & Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97-S101.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
Kelly-Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., & Rook, A. H. (2012). The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. AMERICAN JOURNAL OF HEMATOLOGY, 87(4), 354-360.

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., & Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516-521.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., & Levy, R. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. JOURNAL OF CLINICAL INVESTIGATION, 122(3), 1066-1075.

Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts
Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., & Khavari, P. A. (2012). Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated IncRNAs and novel transcripts. BLOOD, 120.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

The IgG Fc Receptor FcγRIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma
Weng, W. K., Negrin, R., Lavori, P., & Horning, S. J. (2010). The IgG Fc Receptor FcγRIIIa 158 V/F Polymorphism is Correlated with Rituximab-Induced Neutropenia after Autologous Transplantation in Patients with Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab
Weng, W. K., & Levy, R. (2009). Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. LEUKEMIA & LYMPHOMA, 50(5:723-727).

Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma
Weng, W. K., & Levy, R. (2009). Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or Clinical Course in Patients with Follicular Lymphoma. LEUKEMIA & LYMPHOMA, 50(9).

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W.-K., Ingolia, D., & Levy, R. (2009). Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 50(1), 37-46.

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Racila, E., Link, B. K., Weng, W.-K., Witzig, T. E., Ansell, S., & Weiner, G. J. (2008). A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. CLINICAL CANCER RESEARCH, 14(20), 6697-6703.

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Luqman, M., Klabunde, S., Lin, K., Georgakis, G. V., Cherukuri, A., & Younes, A. (2008). The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. BLOOD, 112(3), 711-720.

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy.
Weng, W. K., Czerwinski, D., & Levy, R. (2007). Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless their response to induction chemotherapy. BLOOD, 109.

Immune-mediated antitumor effects with antibody therapy.
Weng WK. (2005). Immune-mediated antitumor effects with antibody therapy. American Society of Clinical Oncology Educational Book.

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., & Levy, R. (2004). Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. JOUNRAL OF CLINICAL ONCOLOGY, 22.

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
Weng, W. K., & Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 21(21), 3940-3947.

Hepatitis C virus (HCV) and lymphomagenesis
Weng, W. K., & Levy, S. (2003). Hepatitis C virus (HCV) and lymphomagenesis. LEUKEMIA & LYMPHOMA, 44(7), 1113-1120.

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Weng, W. K., & Levy, R. (2001). Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. BLOOD, 98(5), 1352-1357.

Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells
Weng, W. K., Shah, N., O'Brien, D., Van Ness, B., & LeBien, T. W. (1997). Differential induction of DNA-binding activities following CD19 cross-linking in human B lineage cells. JOURNAL OF IMMUNOLOGY, 159(11), 5502-5508.

SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS
Weng, W. K., Jarvis, L., & LeBien, T. W. (1994). SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY AND INDUCES FORMATION OF A CD19/VAV/PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX IN HUMAN B-CELL PRECURSORS. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(51), 32514-32521.

FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS
Wolf, M. L., Weng, W. K., STIEGLBAUER, K. T., Shah, N., & LeBien, T. W. (1993). FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS. JOURNAL OF IMMUNOLOGY, 151(1), 138-148.